<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641364</url>
  </required_header>
  <id_info>
    <org_study_id>ART-2019-001</org_study_id>
    <nct_id>NCT04641364</nct_id>
  </id_info>
  <brief_title>Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.</brief_title>
  <official_title>Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I, single-center, randomized, double-blind, placebo-controlled single dose escalation&#xD;
      study, and a positive-controlled multiple dose extension study to evaluate the safety,&#xD;
      tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection in&#xD;
      healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of&#xD;
      recombinant human albumin injection in healthy volunteers. The safety, tolerance,&#xD;
      pharmacokinetics and immunogenicity of recombinant human albumin injection were evaluated in&#xD;
      a single center, randomized, double-blind, placebo-controlled single dose incremental trial&#xD;
      in healthy volunteers. The study was divided into two stages: the first stage was a single&#xD;
      dose and dose increasing stage (including 5 dose groups with increasing dose, and each group&#xD;
      was set with placebo control); the second stage was multiple administration stage (with&#xD;
      positive control). The safety, tolerance, pharmacokinetics, immunogenicity and other early&#xD;
      clinical data of recombinant human albumin were collected and analyzed in the two stages. The&#xD;
      initial dose was 1.25g. The highest dose group was set at 30g. The dose groups of 1.25, 5,&#xD;
      10, 20 and 30 g / time were preset in the single dose stage (dose increasing stage). The&#xD;
      dosage was 10 g / Day in multiple administration stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">May 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>Maximum Plasma Concentration（Cmax）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>time to Maximum Plasma Concentration（Tmax）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>half life (t1/2）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>Red blood cell specific volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>Plasma colloid osmotic pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1-Day 57 for single doses study. Day 1-Day 106 for multiple doses study.</time_frame>
    <description>Percentage of patients with positive reaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Control: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 0.9% sodium chloride injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Human Serum Albumin(HSA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:recombinant human albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human albumin injection</intervention_name>
    <description>single dose or multiple doses of intravenous infusion</description>
    <arm_group_label>Experimental:recombinant human albumin</arm_group_label>
    <other_name>Intravenous infusion of recombinant human albumin injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose intravenous infusion of 0.9% sodium chloride injection</description>
    <arm_group_label>Control: placebo</arm_group_label>
    <other_name>Intravenous infusion of 0.9% sodium chloride injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human albumin injection</intervention_name>
    <description>multiple doses of intravenous infusion</description>
    <arm_group_label>Control: Human Serum Albumin(HSA)</arm_group_label>
    <other_name>Intravenous infusion of human albumin injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1）Informed consent form signed; 2) To be able to complete the study; 3) Subjects (including&#xD;
        partners) are willing to take contraceptive measures; 4) 18-55 years of age; 5) Male&#xD;
        subjects are no less than 50 kg.Female subjects are no less than 45 kg. Body mass index is&#xD;
        18-28kg / m2; 6) Normal cardiac function, defined as left ventricular ejection fraction&#xD;
        (LVEF) ≥ 50%; 7) Physical examination and vital signs are normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cigarettes Smoking subjects.&#xD;
&#xD;
          2. Allergic constitution (multiple drugs and food allergies);&#xD;
&#xD;
          3. History of drug use and/or alcohol abuse;&#xD;
&#xD;
          4. Blood donation or massive blood loss (&gt; 450 mL) within three months before screening;&#xD;
&#xD;
          5. Taking any drugs, prescription, over-the-counter, vitamin products or herbal medicine&#xD;
             within 14 days before screening;&#xD;
&#xD;
          6. Diet or exercise have changed recently;&#xD;
&#xD;
          7. Using study drugs within three months;&#xD;
&#xD;
          8. Risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers;&#xD;
&#xD;
          9. ECG abnormalities (QTc &gt; 470ms for males, &gt; 480ms for females);&#xD;
&#xD;
         10. Female subjects are in lactation. Pregnancy test is positive;&#xD;
&#xD;
         11. Other Clinical laboratory tests abnormalities;&#xD;
&#xD;
         12. Viral screening test is positive, including HBV, HCV, HIV, and Treponema pallidum;&#xD;
&#xD;
         13. Developing Acute disease;&#xD;
&#xD;
         14. Eating chocolate, any caffeine-containing or jaundice-rich food or drink 24 hours&#xD;
             prior to the use of the study drug;&#xD;
&#xD;
         15. Taking any alcoholic products. Alcohol test is positive..&#xD;
&#xD;
         16. Drug test is positive. History of drug abuse or drug use in the past five years;&#xD;
&#xD;
         17. Inability for intravenous injection or blood collection;&#xD;
&#xD;
         18. Using biological products (including live vaccines) within the last 3 months. Planing&#xD;
             to use vaccines during the study period. Having received corticosteroid or human&#xD;
             plasma product system treatment within 1 month.&#xD;
&#xD;
         19. Renal function is abnormal, glomerular filtration rate &lt;80 mL/min (according to the&#xD;
             simplified MDRD formula);&#xD;
&#xD;
         20. History of glaucoma, eye disease.&#xD;
&#xD;
         21. History of cancer or other serious systemic diseases, especially heart, liver, kidney,&#xD;
             digestive tract, nervous system, metabolic abnormalities, immune abnormalities or&#xD;
             mental disorders;&#xD;
&#xD;
         22. History of immunodeficiency or hypofunction;&#xD;
&#xD;
         23. Received major surgery within 2 years.&#xD;
&#xD;
         24. Other subjects by investigator opinion..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, Dr</last_name>
    <role>Study Director</role>
    <affiliation>The first affiliated hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

